CryoLife, Inc. (CRY): Price and Financial Metrics


CryoLife, Inc. (CRY)

Today's Latest Price: $17.67 USD

0.53 (-2.91%)

Updated Jul 9 11:03am

Add CRY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

CRY Stock Summary

  • With a one year PEG ratio of 411.17, Cryolife Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 91.24% of US stocks.
  • CRY's went public 27.42 years ago, making it older than 78.52% of listed US stocks we're tracking.
  • The price/operating cash flow metric for Cryolife Inc is higher than 91.14% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Cryolife Inc are VG, OFIX, WMGI, AMRN, and SILK.
  • CRY's SEC filings can be seen here. And to visit Cryolife Inc's official web site, go to www.cryolife.com.
CRY Daily Price Range
CRY 52-Week Price Range

CRY Stock Price Chart Technical Analysis Charts


CRY Price/Volume Stats

Current price $17.67 52-week high $33.00
Prev. close $18.20 52-week low $12.63
Day low $17.67 Volume 58,682
Day high $18.48 Avg. volume 315,151
50-day MA $21.59 Dividend yield N/A
200-day MA $23.76 Market Cap 666.87M

CryoLife, Inc. (CRY) Company Bio


CryoLife Inc. engages in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac and vascular surgical procedures. The company was founded in 1984 and is based in Kennesaw, Georgia.

CRY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$17.67$2.15-89%

Below please find a table outlining a discounted cash flow forecast for CRY, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Cryolife Inc ranked in the 13th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 88.83%. As for the metrics that stood out in our discounted cash flow analysis of Cryolife Inc, consider:

  • Cryolife Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
  • The weighted average cost of capital for the company is 10. This value is greater than 84.41% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-89%
1%-89%
2%-89%
3%-89%
4%-89%
5%-88%

QGEN, DYNT, IDXX, LCTC, and RGEN can be thought of as valuation peers to CRY, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


CRY Latest News Stream


Event/TimeNews Detail
Loading, please wait...

CRY Latest Social Stream


Loading social stream, please wait...

View Full CRY Social Stream

Latest CRY News From Around the Web

Below are the latest news stories about Cryolife Inc that investors may wish to consider to help them evaluate CRY as an investment opportunity.

CryoLife prices $100M convertible debt offering

CryoLife (CRY) has priced $100M aggregate principal amount of 4.250% convertible senior notes due 2025 in a private placement.Initial purchasers are granted an option to purchase up to an additional $15M of the Notes. The initial conversion rate is 42.6203 shares per $1,000 principal amount of Notes (~$23.46/share).Net proceeds of ~$96.5M...

Seeking Alpha | June 19, 2020

CryoLife Announces Pricing of $100 Million Convertible Senior Notes Offering

ATLANTA, June 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of $100 million aggregate principal amount of 4.250% convertible senior notes due 2025…

PR Newswire | June 19, 2020

CryoLife launches convertible debt offering

CryoLife (CRY) intends to offer $100M aggregate principal amount of convertible senior notes due 2025 in a private placement.Initial purchasers will have an option to purchase up to an additional $15M of the Notes. The interest rate, initial conversion rate, and other terms of the Notes are not yet determined....

Seeking Alpha | June 18, 2020

CryoLife Announces Offering of Convertible Senior Notes Due 2025

ATLANTA , June 18, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY ) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it intends to offer, subject to market conditions and other factors, $100,000,000 aggregate principal amount of convertible senior notes due 2025 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). CryoLife also intends to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $15,000,000 aggregate principal amount of the Notes. The Notes will be senior unsecured...

Benzinga Feeds | June 18, 2020

Coronavirus update: 100 days since COVID-19 declared a pandemic, and U.S. has highest case and death tallies by a wide margin

A full 100 days since the official start of the coronavirus pandemic and the U.S. death toll is approaching 118,000, with new cases still climbing in 20 states, even as governors push to reopen more businesses.

Yahoo | June 18, 2020

Read More 'CRY' Stories Here

CRY Price Returns

1-mo -28.00%
3-mo N/A
6-mo -37.83%
1-year -41.74%
3-year -8.68%
5-year 57.29%
YTD -34.77%
2019 -4.55%
2018 48.20%
2017 0.00%
2016 77.64%
2015 -3.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9487 seconds.